RIVOPHARM Trademark

Trademark Overview


On Tuesday, July 26, 2016, a trademark application was filed for RIVOPHARM with the United States Patent and Trademark Office. The USPTO has given the RIVOPHARM trademark a serial number of 79195512. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, January 19, 2024. This trademark is owned by RIVOPHARM S.A.. The RIVOPHARM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, both prescription and over-the-counter, namely, pharmaceutical preparations for peptic ulcer and gastrooesophageal reflux disease (GORD), propulsives, intestinal anti-infectives, intestinal anti-inflammatory agents, oral pharmaceutical preparations for lowering blood glucose, Vitamin A and D, mixed vitamin preparations consisting of vitamins A and D, vitamin and mineral preparations for medical use, vitamin C in the nature of ascorbic acid mixed vitamin preparations consisting partially of Vitamin C, calcium supplements, mineral supplements, anti-thrombotic agents, intravenous solutions, cardiac glycosides, class I and class III anti-arrhythmics, pharmaceutical preparations for cardiac stimulation excluding cardiac glycosides, Vasodilators used in the treatment of cardiac diseases, anti-adrenergic agents, pharmaceutical preparations for acting on arteriolar smooth muscle, Beta blocking agents, Selective calcium channel blockers, pharmaceutical preparations ...

General Information


Serial Number79195512
Word MarkRIVOPHARM
Filing DateTuesday, July 26, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, January 19, 2024
Registration Number5234473
Registration DateTuesday, July 4, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 18, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations, both prescription and over-the-counter, namely, pharmaceutical preparations for peptic ulcer and gastrooesophageal reflux disease (GORD), propulsives, intestinal anti-infectives, intestinal anti-inflammatory agents, oral pharmaceutical preparations for lowering blood glucose, Vitamin A and D, mixed vitamin preparations consisting of vitamins A and D, vitamin and mineral preparations for medical use, vitamin C in the nature of ascorbic acid mixed vitamin preparations consisting partially of Vitamin C, calcium supplements, mineral supplements, anti-thrombotic agents, intravenous solutions, cardiac glycosides, class I and class III anti-arrhythmics, pharmaceutical preparations for cardiac stimulation excluding cardiac glycosides, Vasodilators used in the treatment of cardiac diseases, anti-adrenergic agents, pharmaceutical preparations for acting on arteriolar smooth muscle, Beta blocking agents, Selective calcium channel blockers, pharmaceutical preparations in the nature of Angiotensin Converting Enzyme inhibitors, pharmaceutical preparations in the nature of Angiotensin Converting Enzyme inhibitors combined with other pharmaceutical preparations, anti-fungals for systemic use, anti-infectives and antiseptics, excluding those combined with corticosteroids, oxytocics, plain corticosteroids for systemic use, thyroid preparations, anti-thyroid preparations, tetracyclines preparations, macrolides, lincosamides and streptogramins, aminoglycoside antibacterials, quinolone antibacterials, antimycotics for systemic use, direct acting antivirals, immune sera, bacterial vaccines, alkylating agents, anti-metabolites, plant alkaloids, cytotoxic antibiotics, hormone antagonists and related agents, namely, anti-estrogens, anti-androgens and enzyme inhibitors, immunosuppressive agents, antiinflammatory and antirheumatic preparations, non-steroids in the nature of butylpyrazolidines, acetic acid derivatives, oxicams, propionic acid derivatives, fenamates, Coxibs, muscle relaxants, peripherally acting agents in the nature of curare alkaloids and choline derivatives, antigout preparations, analgesics and antipyretics preparations, anti-migraine preparations, anti-epileptic preparations, anti-cholinergic agents, dopaminergic agents, anti-psychotics, anxiolytics, hypnotics and sedatives, antidepressants, parasympathomimetics, agents for use against amoebiasis and other protozoal diseases, anti-malarial preparation, adrenergics, inhalant anesthetics, adrenergics for systemic use, antihistamines for systemic use, diuretic agents

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, January 19, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRIVOPHARM S.A.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressCH

Party NameRIVOPHARM S.A.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCH

Party NameRIVOPHARM S.A.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCH

Trademark Events


Event DateEvent Description
Tuesday, November 8, 2016NON-FINAL ACTION WRITTEN
Thursday, November 3, 2016SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Monday, November 7, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, November 7, 2016ASSIGNED TO EXAMINER
Wednesday, November 9, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, November 11, 2016APPLICATION FILING RECEIPT MAILED
Tuesday, November 15, 2016REFUSAL PROCESSED BY MPU
Tuesday, November 15, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, December 9, 2016REFUSAL PROCESSED BY IB
Wednesday, March 1, 2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, March 1, 2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, March 2, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 2, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 2, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 3, 2017ASSIGNED TO LIE
Monday, March 6, 2017DATA MODIFICATION COMPLETED
Monday, March 6, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, March 10, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, March 29, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 29, 2017NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, March 29, 2017NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, April 18, 2017PUBLISHED FOR OPPOSITION
Tuesday, April 18, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 4, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, October 4, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, October 10, 2017FINAL DISPOSITION PROCESSED
Tuesday, October 10, 2017FINAL DISPOSITION NOTICE SENT TO IB
Friday, October 13, 2017NOTIFICATION PROCESSED BY IB
Friday, November 3, 2017FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, July 4, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, January 19, 2024CANCELLED SECTION 71
Friday, September 20, 2024TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Tuesday, September 24, 2024INVALIDATION PROCESSED
Tuesday, September 24, 2024TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sunday, November 17, 2024TOTAL INVALIDATION PROCESSED BY THE IB